A human monoclonal antibody blocking SARS-CoV-2 infection

Abstract

<jats:title>Abstract</jats:title><jats:p>The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19.</jats:p>

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

“…Consequently, lopinavir-ritonavir and remdesevir are currently the only anti-viral drugs included in the more severe case management protocols of COVID-19 [10]. Recent reports described the potential role of human monoclonal antibodies that bind the coronavirus spike receptor binding domain, leading to the neutralization of SARS-CoV2 capability to interact with human target cells [81,82]. However, at the moment these can only be considered as potential treatment options for the future, but they are obviously not available for the management of the current pandemic.…”

SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?

“…Despite its capacity to inhibit infected cells with SARS-S and SARS2-S, the binding activity did not compete with S1B to the ACE2 receptor. This seems to indicate that 47D11 neutralizes SARS-CoV and SARS-CoV-2 through a yet unknown mechanism different from binding interference [6]. This study shows how, despite the high capability of the virus to mutate, targeting conserved core structure of the S1B receptor is a good strategy.…”

A short review on antibody therapy for COVID-19

“…The cross-reactive nature of 47D11 shows that the antibody is more possible to target the conserved core structure of the S1B receptor binding domain. Hence these neutralizing antibodies can reduce the course of virus action in the host or defend an uninfected host that is exposed to the virus [33]. Therefore, targeting the RBD amino acid in SARS-CoV-2 treatment will help scientists to develop effective therapeutic agents to treat and prevent this infection.…”